SEC Comment Letter 0000000000-26-003289 to Evogene Ltd. (EVGN)
Evogene Ltd.
Date: April 1, 2026 · CIK: 0001574565 · Accession: 0000000000-26-003289
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294650
Letter
Re: Evogene Ltd. Registration Statement on Form F-3 Filed March 26, 2026 File No. 333-294650 Dear Ofer Haviv:
April 1, 2026
Ofer Haviv Chief Executive Officer Evogene Ltd. 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Nicholas O'Leary at 202-551-4451 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Industrial
Applications and Services
cc: Jonathan Nathan
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 1, 2026 Ofer Haviv Chief Executive Officer Evogene Ltd. 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel Re: Evogene Ltd. Registration Statement on Form F-3 Filed March 26, 2026 File No. 333-294650 Dear Ofer Haviv: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Nicholas O'Leary at 202-551-4451 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Jonathan Nathan </TEXT> </DOCUMENT>